Building Effective Drugs of Abuse Assays: Conjugates, Kinetics, and Customization

Before we get started



Please use the Q&A button at the bottom of your screen to submit any questions.

There will be a Q&A session at the end of this webinar. If we do not have time to answer your questions, we will reach out by email following the webinar.



This webinar is being recorded. The recording as well as ondemand link will be released following the webinar.

Independent, International, and Industry-Leading Raw Materials Supplier

- Provider of high-quality antibodies, antigens, proteins, enzymes, biospecimens
- Experts in immunoassays, clinical chemistry, molecular diagnostics
- Our portfolio is among the most comprehensive in the IVD industry
- Enabling our customers to develop and manufacture quality IVD tests



Featured Speakers and Panelists



Laura Kolsi, PhD
Technology Manager
Medix Biochemica





Maria Voutilainen, PhD
Global Product Manager











Ella-Maria Vesilahti, MSc

R&D Scientist Medix Biochemica







Laura Kolsi, PhD
Technology Manager
30th September 2025

Contents

- Terminology, Purpose and Applications
- Haptens and Conjugation
- Conjugation Ratio
- Binding Kinetics
- Customization
- Medix Biochemica's Capabilities



Terminology and Definitions


- DoA = Drugs of Abuse, illegal substances and prescription drugs used improperly
- DoA Antigen Conjugate = hapten + protein/label together can trigger an immune response
- Hapten = small molecule that mimics the structure of the analyte and binds to antibody
- Protein/label = Carrier molecule to which hapten is chemically attached



Image: Photo by Unknown Author is licensed under CC BY-SA

Applications – Role of DoA Antigen Conjugates

- Purpose
 - Used in immunoassays to detect specific analytes, especially small molecules like drugs of abuse
- Common assay formats Competitive assays
 - Lateral flow
 - ELISA
 - EMIT



Small molecules conjugated to enzymes (ELISA, EMIT)

ELISA

- Horseradish peroxidase (HRP) (ELISA)
- Signal (color change) is usually inversely proportional to analyte concentration

EMIT

- G6PDH
- Enzyme activity is directly proportional to the analyte concentration







Haptens

Small molecules that include a linker for the protein conjugation

- Small molecules
 - Mw <1000 Da
 - Organic compounds
 - Chemically synthesized or natural products such as alkaloids (morphine, nicotine, cocaine) or hormones
- Designing hapten structure
 - Mimics the structure of the analyte
 - Optimal binding to the antibody
 - · Linker structure, length and conjugation site affects binding








Conjugation

- Hapten is chemically conjugated to the carrier protein/label
 - Typical hapten functional groups taking part in the conjugation: COOH, SH, SCN
 - Conjugation protocols: EDC/NHS or TSTU/DIEA coupling, maleimide conjugation
- Carrier proteins include BSA, HRP, KLH, G6PDH, OVA, BTG
- Lysine and cysteine residues of the protein react with the activated hapten







Image: Crystal structure of BSA Source: RCSB Protein Data Bank



Example of BSA Conjugation of Morphine



Morphine = MOR

Linkers

Morphine BSA conjugate

MOR




Conjugation Ratio

- Conjugation ratio = number of molecules (haptens) attached to protein
- Can have a significant effect on assay performance (eg. sensitivity)
- Finding optimal level important (low vs. high)
 - Risk of overlabeling
 - Steric hindrance
 - Antibody detection
 - Solubility
- Enables monitoring of batch-to batch consistency

Effect of Conjugation Ratio to Assay Sensitivity – 6-MAM-BSA

6-MAM conjugate → lower conjugate ratio resulted in greater sensitivity




Quantified signal intensities in Lateral flow

Figure: Part of poster 'Performance Evaluation of Antibody and Antigen Conjugate Pair for Detection of Heroin Metabolite (6-MAM) in Lateral Flow Assay', medixbiochemica.com



Effect of Conjugation Ratio to Assay Sensitivity – Xylazine

Greater sensitivity with lower conjugation ratio IC50: 7 ng/ml → 3 ng/ml




Competitive ELISA test for Xylazine



Methods for Determining the Conjugation Ratio

Maldi-TOF MS

- Direct measurement
- Analyzing the mass differences in the mass spectrum



TNBSA

- Detection of primary amines using 2,4,6-trinitrobenzene sulfonic acid
- Colorimetric assay
- Quantification via spectrophotometer (335-345 nm)

Image: TNBSA reaction scheme for detection of primary amines | Thermo Fisher Scientific





Binding Kinetics

- Affinity is determined by the equilibrium dissociation constant (K_D), which is the ratio of dissociation (k_{off}) to association (k_{on}).
- Kinetics are especially important with small molecules as they are commonly used in competitive assay set-ups
 - · For example, in lateral flow, fast association rate is an advantage
- At Medix Biochemica, we report kinetic constants measured by our R&D in the product specification sheet

```
100998 Anti-Fentanyl 13101 SPTN-5

Kinetic parameters

Association rate constant 2.2 x 10<sup>6</sup> 1/Ms

Dissociation rate constant 1.2 x 10<sup>-5</sup> 1/s

Affinity constant K<sub>A</sub> = 1.8 x 10<sup>11</sup> 1/M; K<sub>D</sub> = 5.3 x 10<sup>-12</sup> M (= 0.005 nM)

Determination method BLI (Octet RED96e)


Determination antigen Fentanyl-BSA Antigen, Medix Biochemica, 170040
```



Binding Kinetics

- Conjugation site and ratio may affect the binding kinetics with the antibody
 - → Sterical reasons
 - → Orientation of the hapten
- When developing a competitive assay, it is important to optimize binding kinetics between antigen conjugate and antibody

Pair	K _a (K _{on}) 1/Ms	K _d (K _{off}) 1/s	K _A 1/M	K _D M
Clone 1 + Xylazine- hapten:BSA 10:1	2.6 x 10 ⁵	Does not dis	sociate in cond	ditions used.
Clone 1 + Xylazine- hapten:BSA 20:1	7.4 x 10 ⁵	1.7 x 10 ⁻⁵	4.4 x 10 ¹⁰	1.6 x 10 ⁻¹¹



Customization

Why customize

Off-the-shelf conjugates may not meet specific assay requirements

- Matrix effects
- Cross-reactivity (specificity)
- Sensitivity
- Signal intensity and lower the limit of detection

Strategies

- Choice of carrier protein (e.g. BSA, OVA, KLH, HRP)
- Engineering of the protein structure for optimal amount of conjugation sites (eg. Lysines)
- Linker chemistry and hapten orientation (linker length, conjugation site)
- Tuning the conjugation ratio






Medix Biochemica's Capabilities

Medix Biochemica's Capabilities – In-house R&D and Production

- In-house
 - Hapten design: Tailored to mimic the target molecule's structure for optimal binding
 - Synthesis: Performed in-house to ensure purity and consistency
 - Conjugation Controlled processes for optimal performance
 - → Final DoA antigen conjugates available in several grams
 - QC: Constant monitoring of product quality
- ISO13485 certified manufacturing

Benefits of in-house production: better control, high quality and seamless integration with antibody development



Medix Biochemica's Capabilities – Customization

Custom project opportunities for optimal assay performance

- Changing hapten to protein ratio (low/high)
- Tuning conjugation parameters
- Using different carrier proteins

We are open for all opportunities – contact us to discuss more







Maria Voutilainen, PhD
Global Product Manager for Drugs of Abuse
30.9.2025

The Qualified Supplier to the IVD Industry

IVD test manufacturers across the globe trust Medix Biochemica as their partner of choice for IVD raw materials



Quality



Supply Reliability



Scientific Innovation



Comprehensive Portfolio

Clinical Areas Supported

Bone Health Kidney Metabolism **Neurology Tumor Molecular Diagnostics Bulk Biologicals Autoimmunity** Serology Drugs of Abuse Hormones **Clinical Chemistry Infectious Diseases Blood Coagulation** Cardiac Biospecimens

Clinical Areas Supported

Kidney Metabolism Neurology **Tumor** Serology Drugs of Abuse Hormones **Clinical Chemistry**

Medix Biochemica - DoA Portfolio

Antibodies & Antigens Conjugates

Opioids / Opiates

Hallucinogens

Stimulants

Prescription Psychiatric Drugs /TDM

Cannabinoids / **Synthetic Cannabinoids**

Depressants / Sedatives / Hypnotics

Other Psychoactives



- Primary Antibodies
- Conjugates

Drugs of Abuse (DoA) Portfolio Introduction

Opioids / Opiates

- 6-Monoacetylmorphine (6-MAM)
- Buprenorphine (BUP)
- EDDP (Methadone Metabolite)
- Fentanyl
- Hydrocodone

- Methadone
- Morphine
- Oxycodone
- Propoxyphene (PPX)
- Tramadol

Stimulants

- Amphetamine
- Benzoylecgonine (Cocaine)
- MDMA
- MDPV
- Methcathinone
- Methamphetamine

- Methylphenidate
- Methylone
- Mephedrone
- Caffeine
- Nicotine
- Cotinine (Nicotine metabolite)

Other Psychoactives

- Kratom (Mitragynine)
- Salbutamol

Prescription Psychiatric Drugs /TDM

- Aripiprazole
- Clozapine
- Olanzapine
- Quetiapine
- Risperidone
- Tricyclic Antidepressants (TCA)
- Carbamazepine
- Phenytoin (Dilantin)

Cannabinoids / Synthetic Cannabinoids

- Cannabinoids (THC)
- K2
- UR-144
- Pinaca

Depressants / Sedatives / Hypnotics

- Barbiturate
- Oxazepam
- Clonazepam
- Methaqualone
- Zolpidem

- Zopiclone
- Carisoprodol
- Diphenhydramine
- Xylazine

Hallucinogens

- LSD
- Ketamine
- PCP



Antibody and Antigen Conjugate Availability

Drugs of Abuse	Ab	Ag
6-MAM		•
Acetaminophen		•
Amphetamine		•
Barbiturate		•
Benzodiazepine		
Buprenorphine (BUP)		
Caffeine		
Cannabinoids (THC)		•
Carisoprodol		•
Clonazepam		•
Cocaine Metabolite (Benzoylecgonine)		
Cotinine		
Ethanol (EtG)		
Fentanyl		•
Hydrocodone		
K2		
Ketamine		
Kratom (Mitragynine)		
LSD		
MDMA (Ecstasy)		
MDPV		
Methadone		
Methadone metabolites (EDDP)		
Methamphetamine		
Methaqualone		
Methcathinone		

Drugs of Abuse	Ab	Ag
Methylone		•
Methylphenidate		
Morphine		
Nicotine		
Oxazepam		
Oxycodone		
Phencyclidine		
Pinaca		
Propoxyphene (PPX)		•
Tramadol		
UR-144		




6-Monoacetylmorphine (6-MAM)

6-monoacetylmorphine (6-MAM):

Unique metabolite of heroin, and its presence confirms recent heroin use.

Product Type		Catalog #	Description
Monoclonal antibody	0	100983	Anti-6-MAM 12705
		140041	Anti-6-MAM R12703
		HM445	6-Monoacetylmorphine (6-MAM) antibody
	•	HM446	6-Monoacetylmorphine (6-MAM) antibody
		HM461	6-Monoacetylmorphine (6-MAM) antibody
		HM842	6-Monoacetylmorphine (6-MAM) antibody
Polyclonal antibody	0	JP091	6-Monoacetylmorphine (6-MAM) antibody
		JP092	6-Monoacetylmorphine (6-MAM) antibody
		JP093	6-Monoacetylmorphine (6-MAM) antibody
Antigen conjugates	0	170031	6-Monoacetylmorphine (6-MAM)-BSA antigen





Range of Fentanyl Antibodies and Conjugates

Fentanyl:

Synthetic opioid with 50–100 times the potency of morphine.

Product Type		Catalog #	Description
	•	100974	Anti-Fentanyl 13102 SPTN-5
		100998	Anti-Fentanyl 13101 SPTN-5
		100999	Anti-Fentanyl 13103 SPTN-5
Monoclonal antibody		HM004	Fentanyl antibody
		HM1132	Fentanyl antibody
		HM1133	Fentanyl antibody
		HM628	Fentanyl antibody
	•	P01-99-53R-IF	Fentanyl antibody
Polyclonal antibody		P01-99-54R-IF	Fentanyl antibody
		P01-99-55R-IF	Fentanyl antibody
Antigen conjugate		170040	Fentanyl-BSA antigen
		LA008	Fentanyl-BSA antigen
		LA395	Fentanyl-BSA antigen
		LA540	Fentanyl-BSA antigen
		LA556	Fentanyl-BSA antigen

- Fentanyl-specific antibodies allow selective detection of the parent drug.
- Cross-reactive antibodies provide combined recognition of fentanyl and nor fentanyl, increasing the likelihood of detection in screening assays.
- Availability of different antibody types supports assay designs that prioritize either specificity or broader sensitivity.

Range of Fentanyl Antibodies and Conjugates

Fentanyl:

Synthetic opioid with 50–100 times the potency of morphine.

Product Type		Catalog #	Description
	•	100974	Anti-Fentanyl 13102 SPTN-5
		100998	Anti-Fentanyl 13101 SPTN-5
		100999	Anti-Fentanyl 13103 SPTN-5
Monoclonal antibody		HM004	Fentanyl antibody
		HM1132	Fentanyl antibody
		HM1133	Fentanyl antibody
		HM628	Fentanyl antibody
		P01-99-53R-IF	Fentanyl antibody
Polyclonal antibody	•	P01-99-54R-IF	Fentanyl antibody
Polyclonal antibody	•	P01-99-54R-IF P01-99-55R-IF	
Polyclonal antibody	•		Fentanyl antibody
Polyclonal antibody	•	P01-99-55R-IF	Fentanyl antibody Fentanyl antibody
Polyclonal antibody Antigen conjugate	•	P01-99-55R-IF 170040	Fentanyl antibody Fentanyl antibody Fentanyl-BSA antigen
, ,		P01-99-55R-IF 170040 LA008	Fentanyl antibody Fentanyl-BSA antigen Fentanyl-BSA antigen

- Fentanyl-specific antibodies allow selective detection of the parent drug.
- Cross-reactive antibodies provide combined recognition of fentanyl and nor fentanyl, increasing the likelihood of detection in screening assays.
- Availability of different antibody types supports assay designs that prioritize either specificity or broader sensitivity.

NEW Launch: Nitazenes

Available in October 2025

Key Considerations

- Highly potent opioids
 Several analogues far more potent than fentanyl
- Rapidly emerging class
 New structural variants frequently appear in illicit markets
- Challenging detection
 Not yet included in standard opioid screens; may be missed, delaying diagnosis and treatment
- Clinical presentation
 Profound respiratory depression, sedation, and high risk of fatal overdose
- Public health impact
 Increasing prevalence globally; linked to clusters of severe intoxications and deaths

Biologicals, Biospecimens, & Base Matrices

Drugs of Abuse Capabilities

Common Matrix Types				
Urine	991-03			
Saliva	991-05			
Hair	991-14			
Serum	991-24			
Sweat	991-20			
Meconium	991-16			

Analyte Testing (Positive & Negative Options)				
Amphetamines	Methadone			
Barbiturates	Mitragynine			
Buprenorphine	Naloxone			
Benzodiazepines	Naltrexone			
Cocaine/Benzoylecgonine	Opiates			
Ethyl Glucuronide (EtG)	Tricyclic Antidepressants (TCA)			
Fentanyl	THC			
Gabapentin				
Drug Free (Self-Declared)	Drug Free (Certified)			

Why Choose Medix Biochemica Biologicals?				
Urine	High donor counts and testing options support projects with needs ranging from a single positive sample to bulk drug free matrices			
Saliva	Established protocols and recallable donors allow for high volume access with adaptable collection methods			
Sweat	Single donor samples to bulk volumes with optional testing - all collected under controlled conditions			
Hair	Recallable donors allow for time-course studies and the option for sample pairing with other matrices			
Meconium	Availability of a difficult to source neonatal specimen that is collected in accordance with regulatory guidelines			
Serum	Either positive or negative , samples available with high donor counts and pre-screened testing			
General	Customization for any collection (whether demographic or process) along with the ability to offer paired matrices			



Exclusive Offer of Free DoA Samples

Exclusive Offer: Free Samples

We are offering <u>free</u>
<u>samples of our selected</u>
<u>DoA antibodies and</u>
<u>antigen conjugates</u> for a limited time.

Test our products and provide feedback!

Antibody 6-MAM Acetaminophen Benzoylecgonine (Cocaine) Buprenorphine (BUP) Cannabinoids (THC) Clonazepam Ethanol (EtG) Fentanvl Ketamine Kratom (Mitragynine) LSD **MDMA** Methadone Morphine Oxycodone PCP Pinaca Propoxyphene (PPX) Tramadol Tricyclic Antidepressant (TCA) UR-144 Xylazine

Antigen Conjugate 6-MAM **Amphetamine** Benzoylecgonine (Cocaine) Cannabinoids (THC) Carisoprodol Clonazepam Cotinine Fentanyl Hvdrocodone K2 Ketamine **MDMA** Methaqualone Methylphenidate Morphine **PCP** Propoxyphene (PPX) Tramadol Tricyclic Antidepressant (TCA) Zolpidem

Not seeing your analyte of interest?
Let us know which ones and we'll be in touch on what we can offer



Did you enjoy the webinar?

Share your feedback:





Subscribe to stay informed on all Medix Biochemica webinars:



